Cardiovascular disease represents a continuum that starts with risk factors such as hypertension and progresses to atherosclerosis, end-organ damage, and ultimately to chronic heart failure (CHF) and premature death. Renin-angiotensin system (RAS) blockade with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin II type 1 receptor blockers (ARBs) has turned out to be beneficial at all stages of this continuum. Several mechanisms govern the progression of structural myocardial damage to end-stage CHF. Chronic neuroendocrine activation fosters left ventricular remodeling and dilatation and leads to clinical symptoms of CHF via forward/backward failure. RAS inhibition is a cornerstone of neuroendocrine blockade in CHF patients, and combined RAS blockade is especially effective in patients presenting with repetitive cardiac decompensations. This review focuses on the therapeutic role of inhibitors of different RAS components in chronic heart failure caused by systolic left ventricular dysfunction.
Arnold, J.M. , Yusuf, S. , Young, J. , Mathew, J. , Johnstone, D. , Avezum, A. et al. (2003) Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study . Circulation107: 1284-1290.
2.
Böhm, M. (2007) Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?Am J Cardiol100: 38J-44J.
3.
Böhm, M. , Kilter, H. and Kindermann, M. (2003) Mechanisms contributing to the progression of LV dysfunction to endstage heart failure . Eur Heart J24: 114-121.
4.
Bosch, J. , Yusuf, S. , Gerstein, H.C. , Pogue, J. , Sheridan, P. , Dagenais, G. et al. (2006) Effect of ramipril on the incidence of diabetes . N Engl J Med355: 1551-1562.
5.
Braunwald, E. , Domanski, M.J. , Fowler, S.E. , Geller, N.L. , Gersh, B.J. , Hsia, J. et al. (2004) Pfeffer, M.A., Rice, M.M . , Rosenberg, Y.D., Rouleau, JL: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med351: 2058-2068.
6.
Brown, J.D. and Plutzky, J. (2007) Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets . Circulation115: 518-533.
7.
Carr, A.A. , Kowey, P.R. , Devereux, R.B. , Brenner, B.M. , Dahlöf, B. , Ibsen, H. et al. (2005) Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies . Am J Cardiol96: 1530-1536.
8.
Carson, P. , Massie, B.M. , McKelvie, R. , McMurray, J. , Komajda, M. , Zile, M. et al. (2005) The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design . J Card Fail11: 576-585.
9.
Cohn, J.N. and Tognoni, G. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure . N Engl J Med345: 1667-1675.
10.
Dahlöf, B. , Devereux, R.B. , Kjeldsen, S.E. , Julius, S. , Beevers, G. , de Faire, U. et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol . Lancet359: 995-1003.
11.
Dickstein, K. and Kjekshus, J. (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan . Lancet360: 752-760.
12.
Dzau, V. and Braunwald, E. (1991) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement . Am Heart J121: 1244-1263.
13.
Fox, K.M. (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) . Lancet362: 782-788.
14.
Friedrich, E.B. , Teo, K.K. and Böhm, M. (2006) ACE inhibition in secondary prevention: are the results controversial ? Clin Res Cardiol. 95: 61-67.
15.
Granger, C.B. , McMurray, J.J. , Yusuf, S. , Held, P. , Michelson, E.L. , Olofsson, B. et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial . Lancet362: 772-776.
16.
Hansson, L. , Lindholm, L.H. , Niskanen, L. , Lanke, J. , Hedner, T. , Niklason, A. et al. (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial . Lancet353: 611-616.
17.
Ho, K.K. , Pinsky, J.L. , Kannel, W.B. and Levy, D. (1993) The epidemiology of heart failure: the Framingham Study . J. Am Coll Cardiol22: 6A-13A.
18.
Hoppe, U.C. (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next ? AT1-receptor antagonists? Clin Res Cardiol96: 196-198.
19.
Hunt, S.A. , Abraham, W.T. , Chin, M.H. , Feldman, A.M. , Francis, G.S. , Ganiats, T.G. et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society . Circulation112: e154-e235.
20.
Kindermann, M. , Adam, O. , Werner, N. and Böhm, M. (2007) Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007 (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO) . Clin Res Cardiol96: 767-786.
21.
Kjekshus, J. , Apetrei, E. , Barrios, V. , Böhm, M. , Cleland, J.G. , Cornel, J.H. et al. (2007) Rosuvastatin in older patients with systolic heart failure . N Engl J Med357: 2248-2261.
22.
Kjeldsen, S.E. , Julius, S. , Mancia, G. , McInnes, G.T. , Hua, T. , Weber, M.A. et al. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial . J Hypertens24: 1405-1412.
23.
Krum, H. , Carson, P. , Farsang, C. , Maggioni, A.P. , Glazer, R.D. , Aknay, N. et al. (2004) Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT . Eur J Heart Fail6: 937-945.
24.
Lonn, E. , Shaikholeslami, R. , Yi, Q. , Bosch, J. , Sullivan, B. , Tanser, P. et al. (2004) Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the heart outcomes prevention evaluation (HOPE) Trial . J Am Coll Cardiol43: 2200-2206.
25.
McKelvie, R.S. , Yusuf, S. , Pericak, D. , Avezum, A. , Burns, R.J. , Probstfield, J. et al. (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators . Circulation100: 1056-1064.
26.
McMurray, J.J. , Ostergren, J. , Swedberg, K. , Granger, C.B. , Held, P. , Michelson, E.L. et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial . Lancet362: 767-771.
27.
McMurray, J. , Solomon, S. , Pieper, K. , Reed, S. , Rouleau, J. , Velazquez, E. et al. (2006) The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the valsartan in acute myocardial infarction trial (VALIANT) . J Am Coll Cardiol47: 726-733.
28.
Menard, J. and Azizi, M. (2007) The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren . J Hypertens25: 1775-1782.
29.
Mochizuki, S. , Dahlöf, B. , Shimizu, M. , Ikewaki, K. , Yoshikawa, M. , Taniguchi, I. et al. (2007) Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study . Lancet369: 1431-1439.
30.
Nickenig, G. and Harrison, D.G. (2002) The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis . Circulation105: 393-396.
31.
Okunishi, H. , Miyazaki, M. and Toda, N. (1984) Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall . J Hypertens2: 277-284.
32.
Pepine, C.J. and Probstfield, J.L. (2004) A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients . CME monograph; UF College of Medicine. Vasc Biol Clin Pract6: 1-6.
33.
Pfeffer, M.A. , McMurray, J.J. , Velazquez, E.J. , Rouleau, J.L. , Kober, L. , Maggioni, A.P. et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both . N Engl J Med349: 1893-1906.
34.
Phillips, C.O. , Kashani, A. , Ko, D.K. , Francis, G. and Krumholz, H.M. (2007) Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials . Arch Intern Med167: 1930-1936.
35.
Pitt, B. , O'Neill, B. , Feldman, R. , Ferrari, R. , Schwartz, L. , Mudra, H. et al. (2001) The quinapril ischemic event trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function . Am J Cardiol87: 1058-1063.
36.
Pitt, B. , Poole-Wilson, P.A. , Segal, R. , Martinez, F.A. , Dickstein, K. , Camm, A.J. et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II . Lancet355: 1582-1587.
37.
Recio-Mayoral, A. , Kaski, J.C. , McMurray, J.J. , Horowitz, J. , van Veldhuisen, D.J. and Remme, W.J. (2007) Clinical Trials Update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT,
38.
Finesse,Prague-8, CARESS in MI and ACUITY . Cardiovasc Drugs Ther21: 459-465.
39.
Scaglione, R. , Argano, C. , Di Chiara, T. , Parrinello, G. , Colomba, D. , Avellone, G. et al. (2007) Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients . J Hum Hypertenss21: 307-315.
40.
Scheen, A.J. (2004) Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system . Drugs64: 2537-2565.
41.
Schefe, J.H. , Menk, M. , Reinemund, J. , Effertz, K. , Hobbs, R.M. , Pandolfi, P.P. et al. (2006) A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein . Circ Res99: 1355-1366.
42.
Schupp, M. , Clemenz, M. , Gineste, R. , Witt, H. , Janke, J. , Helleboid, S. et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity . Diabetes54: 3442-3452.
43.
Solomon, S.D. , Skali, H. , Anavekar, N.S. , Bourgoun, M. , Barvik, S. , Ghali, J.K. et al. (2005) Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction . Circulation111: 3411-3419.
44.
Solomon, S.D. , Wang, D. , Finn, P. , Skali, H. , Zornoff, L. , McMurray, J.J. et al. (2004) Effect of candesartan on cause-specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program . Circulation110: 2180-2183.
45.
Teo, K. , Yusuf, S. , Sleight, P. , Anderson, C. , Mookadam, F. , Ramos, B. et al. (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials . Am Heart J148: 52-61.
46.
The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS) . N Engl J Med316: 1429-1435.
47.
Van der Horst, I. , Voors, A.A. and van Veldhuisen, D.J. (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?Clin. Res. Cardiol. 96: 193-195.
48.
Wassmann, S. and Nickenig, G. (2006) Pathophysiological regulation of the AT1-receptor and implications for vascular disease . J Hypertens Suppl24: S15-S21.
49.
Wright, J.T. for the ALLHAT Collaborative Research Group. (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) . JAMA288: 2981-2997.
50.
Yusuf, S. , Sleight, P. , Pogue, J. , Bosch, J. , Davies, R. and Dagenais, G. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators . N Engl J Med342: 145-153.
51.
Yusuf, S. , Pfeffer, M.A. , Swedberg, K. , Granger, C.B. , Held, P. , McMurray, J.J. et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial . Lancet362: 777-781.
52.
Zanchetti, A. , Julius, S. , Kjeldsen, S. , McInnes, G.T. , Hua, T. , Weber, M. et al. (2006) Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial . J Hypertens24: 2163-2168.
